Page last updated: 2024-08-23

raloxifene hydrochloride and Ovarian Neoplasms

raloxifene hydrochloride has been researched along with Ovarian Neoplasms in 13 studies

Research

Studies (13)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (15.38)	18.2507
2000's	9 (69.23)	29.6817
2010's	2 (15.38)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
D'Antona, D; Gizzo, S; Litta, P; Nardelli, GB; Noventa, M; Saccardi, C	1
Burdette, JE; Davis, DA; Dean, M; Moyle-Heyrman, G; Schipma, MJ	1
Neves-E-Castro, M	1
Busacca, M; Chiodo, I; Infantino, M; Matrone, R; Somigliana, E; Viganò, P; Vignali, M	1
Oh, AS; Reiter, R; Riegel, AT; Wellstein, A	1
Chen, Z; Edusa, V; Fadiel, A; Fishman, DA; Naftolin, F; Sakamoto, H; So, J; Song, J	1
Ezoe, S; Hayakawa, J; Kamegai, H; Kanakura, Y; Kanemura, M; Matsumura, I; Ohmichi, M; Sakata, M; Sasaki, H; Seino-Noda, H; Tanabe-Kimura, A; Tasaka, K; Terai, Y	1
Ziegler, J	1
Fackenthal, JD; Olopade, MD; Olufunmilayo, I	1
Senior, K	1
Emons, G; Westphalen, S	1
Ciaccia, AV; Goldstein, SR; Muram, D; Neven, P; Silfen, SL; Zhou, L	1

Reviews

3 review(s) available for raloxifene hydrochloride and Ovarian Neoplasms

Article	Year
Association of ovarian and uterine cancers with postmenopausal hormonal treatments. Clinical obstetrics and gynecology, 2008, Volume: 51, Issue:3 Topics: Estrogen Replacement Therapy; Estrogens; Female; Humans; Norpregnenes; Ovarian Neoplasms; Postmenopause; Progestins; Raloxifene Hydrochloride; Risk Factors; Tamoxifen; Uterine Neoplasms	2008
Endometriosis: novel etiopathogenetic concepts and clinical perspectives. Fertility and sterility, 2002, Volume: 78, Issue:4 Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents; Aromatase Inhibitors; Endometriosis; Enzyme Inhibitors; Female; Humans; Immunity, Cellular; MEDLINE; Ovarian Cysts; Ovarian Diseases; Ovarian Neoplasms; Postmenopause; Raloxifene Hydrochloride; Rectal Diseases; Selective Estrogen Receptor Modulators; Vaginal Diseases	2002
Breast cancer genetics. Implications of clinical practice. Hematology/oncology clinics of North America, 2000, Volume: 14, Issue:3 Topics: Age of Onset; Anticarcinogenic Agents; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Breast Neoplasms, Male; Carcinoma; Case Management; Cyclin D1; DNA Mutational Analysis; Estrogen Antagonists; Female; Gene Frequency; Genes, BRCA1; Genes, erbB-2; Genetic Counseling; Genetic Testing; Humans; Male; Mammography; Mastectomy; Neoplasm Proteins; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Oncogenes; Ovarian Neoplasms; Ovariectomy; Phenotype; Raloxifene Hydrochloride; Retrospective Studies; Risk; Tamoxifen; Transcription Factors	2000

Other Studies

10 other study(ies) available for raloxifene hydrochloride and Ovarian Neoplasms

Article	Year
Proposal on Raloxifene use after prophylactic salpingo-oophorectomy in BRCA1-2: hypothesis and rationale. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2014, Volume: 23, Issue:6 Topics: Bone and Bones; Bone Density Conservation Agents; BRCA1 Protein; BRCA2 Protein; Cardiovascular System; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Ovariectomy; Prophylactic Surgical Procedures; Raloxifene Hydrochloride; Salpingectomy	2014
Genome-wide transcriptional regulation of estrogen receptor targets in fallopian tube cells and the role of selective estrogen receptor modulators. Journal of ovarian research, 2016, Feb-15, Volume: 9 Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma in Situ; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Fallopian Tubes; Female; Gene Expression Regulation, Neoplastic; Genome; Humans; Mice; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Piperidines; Raloxifene Hydrochloride; Receptors, Estrogen; Tamoxifen; Thiophenes; Transcriptome	2016
Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity. Oncogene, 2004, Jan-15, Volume: 23, Issue:2 Topics: Breast Neoplasms; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Gene Expression Regulation, Neoplastic; Genistein; Humans; Ligands; Nuclear Receptor Coactivator 3; Ovarian Neoplasms; Protein Isoforms; Raloxifene Hydrochloride; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription Factors	2004
Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer letters, 2005, Mar-18, Volume: 220, Issue:1 Topics: Cell Division; Cell Survival; Collagen; Cytoskeletal Proteins; Dose-Response Relationship, Drug; Drug Combinations; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gene Expression Regulation, Neoplastic; Humans; Laminin; Ovarian Neoplasms; Phosphoproteins; Proteoglycans; Raloxifene Hydrochloride; Tamoxifen; Tumor Cells, Cultured	2005
Difference between genomic actions of estrogen versus raloxifene in human ovarian cancer cell lines. Oncogene, 2008, Apr-24, Volume: 27, Issue:19 Topics: Cell Line, Tumor; Estrogen Receptor alpha; Estrogens; Female; Genome, Human; Humans; Insulin-Like Growth Factor I; Ovarian Neoplasms; Proto-Oncogene Proteins c-myc; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators	2008
Raloxifene, retinoids, and lavender: "me too" tamoxifen alternatives under study. Journal of the National Cancer Institute, 1996, Aug-21, Volume: 88, Issue:16 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Clinical Trials as Topic; Drugs, Investigational; Estrogen Antagonists; Female; Humans; Lavandula; Male; Neoplasms; Oils, Volatile; Ovarian Neoplasms; Piperidines; Plant Oils; Plants, Medicinal; Prostatic Neoplasms; Raloxifene Hydrochloride; Retinoids; Tamoxifen; Toremifene	1996
Preventing "unpreventable" cancers. Harvard women's health watch, 1999, Volume: 7, Issue:3 Topics: Breast Neoplasms; Estrogen Antagonists; Female; Humans; Mastectomy; Ovarian Neoplasms; Raloxifene Hydrochloride; Risk Factors; Tamoxifen	1999
Raloxifene encourages growth of ovarian cancer cells in vitro news. The Lancet. Oncology, 2001, Volume: 2, Issue:8 Topics: Cell Division; Female; Humans; Ovarian Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tumor Cells, Cultured	2001
[Hormone replacement therapy in peri- and postmenopause. Routine use is not indicated]. MMW Fortschritte der Medizin, 2002, Feb-28, Volume: 144, Issue:9 Topics: Alzheimer Disease; Breast Neoplasms; Cardiovascular Diseases; Clinical Trials as Topic; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Hormone Replacement Therapy; Humans; Middle Aged; Osteoporosis, Postmenopausal; Ovarian Neoplasms; Primary Prevention; Progestins; Raloxifene Hydrochloride; Risk Factors; Selective Estrogen Receptor Modulators; Thrombosis; Time Factors	2002
The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecologic oncology, 2002, Volume: 85, Issue:2 Topics: Aged; Aged, 80 and over; Female; Humans; Incidence; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Postmenopause; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2002